Table A3.
Blood Circulating Biomarker Levels at Baseline and Changes During Treatment in Patients With NF2-Associated VSs
| Biomarker | Median (IQR) | |||
|---|---|---|---|---|
| Pretreatment | Percent Change | |||
| During Treatment | Post-Treatment | |||
| Baseline (pg/ml; n = 13) | Week 25 (n = 13) | Week 49 (n = 12) | Week 72 (n = 11) | |
| Free VEGF | 182 (107-237) | 0.15 (0.12-0.23) | 0.16 (0.12-0.31) | 0.21 (0.80-0.43) |
| P | NA | < .001 | < .001 | < .001 |
| Total VEGF (free plus bound) | 131 (68-197) | 7.34 (5.07-10.89) | 7.53 (4.87-9.49) | 0.45 (0.32-0.60) |
| P | NA | < .001 | < .001 | < .001 |
| PlGF | 35 (33-41) | 1.93 (1.53-2.40) | 2.37 (1.69-3.12) | 1.21 (1.03-1.44) |
| P | NA | .0034 | < .001 | .014 |
| VEGF-C | 234 (190-316) | 0.88 (0.71-1.35) | 1.20 (0.62-1.65) | 0.70 (0.41-0.81) |
| P | NA | .95 | .68 | .054 |
| VEGF-D | 1,019 (879-1,366) | 0.96 (0.93-1.15) | 1.07 (1.01-1.24) | 1.05 (0.87-1.12) |
| P | NA | .68 | .034 | .58 |
| sVEGFR1 | 79 (64-94) | 0.89 (0.80-1.12) | 0.92 (0.79-1.31) | 0.86 (0.82-0.95) |
| P | NA | .68 | .97 | .068 |
| sVEGFR2 | 11,108 (9,296-12,065) | 0.95 (0.93-1.05) | 0.92 (0.88-1.05) | 0.96 (0.86-1.13) |
| P | NA | .50 | .38 | .64 |
| bFGF | 79 (43-93) | 1.02 (0.48-1.18) | 1.28 (0.69-1.57) | 0.50 (0.24-0.74) |
| P | NA | .38 | .27 | .054 |
| Ang1 | 5,274 (3,996-6,953) | 1.02 (0.48-1.18) | 1.28 (0.73-2.26) | 0.58 (0.29-0.95) |
| P | NA | 1.00 | .23 | .067 |
| Ang2 | 1,654 (1,422-1,938) | 0.81 (0.74-0.97) | 0.91 (0.78-1.03) | 1.09 (0.99-1.23) |
| P | NA | .0093 | .23 | .10 |
| sTie2 | 6,937 (5,773-8,271) | 0.97 (0.87-1.03) | 0.89 (0.85-1.03) | 1.00 (0.90-1.21) |
| P | NA | .19 | .34 | .83 |
| HGF | 848 (772-1,016) | 1.01 (0.90-1.20) | 1.06 (1.01-1.31) | 1.09 (0.97-1.17) |
| P | NA | .45 | .052 | .24 |
| s-cMet | 1,349 (1,186-1,478) | 0.97 (0.92-1.06) | 0.99 (0.93-1.04) | 1.00 (0.96-1.03) |
| P | NA | .38 | .678 | .90 |
| CAIX | 47 (32-52) | 1.84 (0.75-2.16) | 1.52 (0.64-2.11) | 1.16 (0.64-1.71) |
| P | NA | .094 | .052 | .24 |
| IL-1α | 1.4 (1.0-2.4) | 0.97 (0.84-1.07) | 1.15 (0.72-3.02) | 1.03 (0.70-1.39) |
| P | NA | .64 | .34 | .70 |
| IL-6 | 2.4 (1.9-3.1) | 1.23 (0.97-1.63) | 1.01 (0.84-1.30) | 1.07 (0.91-1.45) |
| P | NA | .094 | .68 | .21 |
| IL-8 | 4.8 (3.3-5.8) | 1.08 (0.88-1.23) | 1.07 (0.81-1.41) | 0.98 (0.67-1.24) |
| P | NA | .59 | .52 | .64 |
| TNF-α | 7.8 (7.5-1.0) | 1.00 (0.91-1.06) | 0.99 (0.85-1.23) | 0.88 (0.71-1.30) |
| P | NA | .89 | .68 | 1.00 |
| SDF1α | 1,972 (1,789-2,107) | 1.02 (1.00-1.14) | 1.07 (1.01-1.12) | 1.00 (0.91-1.04) |
| P | NA | .38 | .0093 | .52 |
NOTE. Bold font indicates statistical significance. P values determined from Wilcoxon sign rank test for percentage of change after treatment.
Abbreviations: Ang, angiopoietin; bFGF, basic fibroblast growth factor; CAIX, carbonic anhydrase IX; HGF, hepatocyte growth factor; IL, interleukin; IQR, interquartile range; NA, not applicable; NF2, neurofibromatosis type 2; PlGF, placental growth factor; SDF1α, stromal cell–derived factor 1α; sVEGFR, soluble vascular endothelial growth factor receptor; TNF-α, tumor necrosis factor alpha; VEGF, vascular endothelial growth factor; VS, vestibular schwannoma.